Sarepta Therapeutics Inc.'s proposed Duchenne muscular dystrophy treatment eteplirsen may have been doomed by the optimism created from its early study results, which it turned out could not be replicated.
And now the company finds itself in a precarious situation as it looks for a way to generate additional scientific data that match the overwhelmingly positive anecdotal evidence of efficacy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?